Connect Biopharma Holdings Ltd
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of inflammatory diseases in the United States. The company's lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is in Phase 3 studies for the treatment of inflammatory diseases such as a… Read more
Connect Biopharma Holdings Ltd (CNTB) - Total Assets
Latest total assets as of September 2025: $67.36 Million USD
Based on the latest financial reports, Connect Biopharma Holdings Ltd (CNTB) holds total assets worth $67.36 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Connect Biopharma Holdings Ltd - Total Assets Trend (2018–2024)
This chart illustrates how Connect Biopharma Holdings Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Connect Biopharma Holdings Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Connect Biopharma Holdings Ltd's total assets of $67.36 Million consist of 95.7% current assets and 4.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 77.2% |
| Accounts Receivable | $1.05 Million | 1.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $53.00K | 0.1% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Connect Biopharma Holdings Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Connect Biopharma Holdings Ltd's current assets represent 95.7% of total assets in 2024, a decrease from 98.3% in 2018.
- Cash Position: Cash and equivalents constituted 77.2% of total assets in 2024, down from 88.5% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 1.0% of total assets.
Connect Biopharma Holdings Ltd Competitors by Total Assets
Key competitors of Connect Biopharma Holdings Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Connect Biopharma Holdings Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Connect Biopharma Holdings Ltd generates 0.26x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Connect Biopharma Holdings Ltd is currently not profitable relative to its asset base.
Connect Biopharma Holdings Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.48 | 12.04 | 13.24 |
| Quick Ratio | 5.48 | 12.07 | 12.44 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $51.17 Million | $ 106.27 Million | $ 48.66 Million |
Connect Biopharma Holdings Ltd - Advanced Valuation Insights
This section examines the relationship between Connect Biopharma Holdings Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.69 |
| Latest Market Cap to Assets Ratio | 0.34 |
| Asset Growth Rate (YoY) | -19.5% |
| Total Assets | $101.28 Million |
| Market Capitalization | $34.61 Million USD |
Valuation Analysis
Below Book Valuation: The market values Connect Biopharma Holdings Ltd's assets below their book value (0.34 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Connect Biopharma Holdings Ltd's assets decreased by 19.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Connect Biopharma Holdings Ltd (2018–2024)
The table below shows the annual total assets of Connect Biopharma Holdings Ltd from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $101.28 Million | -19.55% |
| 2023-12-31 | $125.89 Million | -28.88% |
| 2022-12-31 | $177.01 Million | -39.25% |
| 2021-12-31 | $291.39 Million | +75.33% |
| 2020-12-31 | $166.19 Million | +207.45% |
| 2019-12-31 | $54.05 Million | -21.98% |
| 2018-12-31 | $69.29 Million | -- |